$ALLR News

Allarity Therapeutics Q1 EPS $(0.17) Beats $(0.22) Estimate, Sales $25.000K

Allarity Therapeutics Says API Manufacturing Campaign For Stenoparib Is Progressing In Line With Planned Timeline For Completion No Later Than Q3 Of 2026 At CDMO

Allarity Therapeutics Says USPTO Issues Notice Of Allowance For Patent Application Covering DRP Companion Diagnostic Specific To Stenoparib

Allarity Therapeutics Says USPTO Issues Notice Of Allowance For Patent Application Covering DRP Companion Diagnostic Specific To Stenoparib

Ascendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $9.75

Allarity Therapeutics Q4 EPS $(0.21), Inline, Sales $320.000K

Allarity Therapeutics Closes $20M Non-Convertible Debt Funding With Streeterville Capital; Expects Cash Runway To Support Operations Through Mid-2028

Allarity Therapeutics shares are trading higher. The company announced that the first patients have been dosed with stenoparib and temozolomide in the VA-funded Phase 2 trial for small cell lung cancer treatment.

Allarity Therapeutics Doses the First Patients With Stenoparib And Temozolomide In VA-Funded Investigator-Initiated Phase 2 Trial For Relapsed Small Cell Lung Cancer

Allarity Therapeutics Files Prospectus For Offering 255K Common Shares By Selling Stockholder

Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran’s Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment

Allarity Therapeutics Starts Enrollment For Phase 2 Trial To Developing Senoparib

Allarity CEO says 2026 represents an ‘inflection point’

Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders

Allarity Therapeutics Files Prospectus To Offer Up To $50M In Various Securities

Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates

Allarity Therapeutics Q3 EPS $(0.19) Beats $(0.21) Estimate

Ascendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $9.25

Reported Earlier: Allarity Therapeutics Enters Into A Securities Purchase Agreement; Secures $2.5M

Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months